Emcure Pharmaceuticals, a prominent player in the women’s healthcare sector, celebrated a remarkable achievement on World Diabetes Day by securing a place in the Asia Book of Records. The company orchestrated the largest virtual campaign focused on women’s diabetes awareness, engaging 20,000 healthcare professionals (HCPs) to highlight critical lifestyle adjustments for diabetes management in women.
In 2022, diabetes prevalence among women aged 18 and above in India reached 23.7%. Research suggests that around 8-10% of Indian women are affected by diabetes, although this figure varies across different regions, age groups, and between urban and rural settings. Lifestyle factors contribute to higher rates in urban areas, while rural regions are witnessing a rise in cases.
This awareness drive, launched at the esteemed 52nd Annual Conference of the Research Society for the Study of Diabetes in India (RSSDI) in Delhi, presents an in-depth “9 Steps” strategy for managing and preventing diabetes in women. This evidence-based model, crafted in collaboration with a network of over 20,000 healthcare experts, targets the specific hurdles faced by women with diabetes.
During the RSSDI meeting in Delhi on November 15, 2024, a ‘9-Steps’ poster was unveiled to emphasize the significance of effective lifestyle changes and diabetes control. Additionally, the momentous recognition from the Asia Book of Records was officially celebrated during this event.
Part of Emcure’s “SAKHI” initiative, this campaign underscores the company’s dedication to enhancing women’s health through innovative strategies in disease prevention and management. Emcure, based in Pune, stands as a leading pharmaceutical corporation in India, renowned for its commitment to innovation, quality, and a patient-centric approach. As a research-driven organization, Emcure develops and markets a diverse range of pharmaceutical products aimed at improving health and well-being across various major therapeutic areas.
Founded in 1981, Emcure ranks as the 12th largest pharmaceutical company in India in terms of domestic sales for MAT June 2024. Its global presence spans over 70 countries, including regions in Europe and Canada.